Portfolio News
Sofinnova Capital
Avantium reaches key commercial milestone for its FDCA flagship plant with commitments for >50% of its output
Avantium N.V., a leading technology company in renewable chemistry, announces that it has signed a conditional offtake agreement with Resilux, an international rigid plastic packaging supplier, for the supply of PEF resin from the planned Avantium FDCA flagship plant. This brings the total of such offtake contracts to five.
Related Strategy
Industrial BiotechRelated Company
AvantiumAMSTERDAM, 7 April 2021, 18:00 hrs CEST – Avantium N.V., a leading technology company in renewable chemistry, announces that it has signed a conditional offtake agreement with Resilux, an international rigid plastic packaging supplier, for the supply of PEF resin from the planned Avantium FDCA flagship plant. This brings the total of such offtake contracts to five.
The planned FDCA flagship plant is set to produce 5 kilotonnes of FDCA (furandicarboxylic acid) per annum, the key building block for the 100% fossil-free, recyclable polymer PEF (polyethylene furanoate). Including an additional commitment from one of the previously announced offtake partners, the five conditional offtake agreements represent a total offtake volume of over 50% of the FDCA production capacity from the flagship plant. This marks an important step towards a positive Final Investment Decision (FID) for the construction of the world’s first commercial FDCA plant, which Avantium would plan to open in 2023.
Related News
Mediar Therapeutics enters into global licensing agreement with Lilly to advance first-in-class WISP1 antibody for the treatment of idiopathic pulmonary fibrosis (IPF)
Global debut in an ASC setting at Surgeon's Point Surgery Center for Moon Surgical's Maestro System
Tenpoint Therapeutics announces positive topline data from Phase 3 pivotal study, BRIO-II, of BRIMOCHOL™ PF for the treatment of presbyopia
Bon Vivant achieves self-affirmed GRAS status, notifying the FDA of its recombinant whey protein enabling commercialization in the U.S.
Noema Pharma Appoints Michael Samar as Chief Financial Officer